Myocardial Energetics and SGLT2i in HF
HFpEF
LITTLE
The presented results do not indicate changes in cardiac energetics (PCr/ATP) after treatment with empagliflozin in nonischemic, mostly nondiabetic patients with HFrEF and with HFpEF. In HFrEF, the failing heart shows an overall decrease in fatty acid oxidation and an increase of glycolysis.Little is known about cardiac energetics and substrate metabolism in HFpEF. It was previously established that HFpEF hearts are energy deprived.